Results 41 to 50 of about 16,330 (302)
Novel Designer Benzodiazepines: Comprehensive Review of Evolving Clinical and Adverse Effects
Neurology International, 2022 As tranquilizers, benzodiazepines have a wide range of clinical uses. Recently, there has been a significant rise in the number of novel psychoactive substances, including designer benzodiazepines.
Amber N. Edinoff +9 more
doaj +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Central nervous system (CNS) neuroblastoma, FOXR2‐activated, is a recently recognized entity in the WHO CNS5 classification, defined by activation of the FOXR2 transcription factor and unique histopathological features. This review synthesizes available literature and pooled clinical data, providing insight into demographics ...
Sudarshawn Damodharan +1 more
wiley +1 more source
Acute health problems due to recreational drug use in patients presenting to an urban emergency department in Switzerland [PDF]
, 2015 QUESTIONS UNDER STUDY: To describe acute toxicity of recreational drugs including novel psychoactive substances. METHODS: We included all cases presenting at the emergency department (ED) of the University Hospital of Basel, Switzerland, between ...
Dolder, Patrick C. +9 more
core +1 more source
Conventional psychoactive substances in the shadow of designer drugs [PDF]
, 2023 Suvremeno doba obilježava porast konzumacije novih ili dizajnerskih droga (engl. „designer drugs“), a ova skupina uključuje sintetske katinone, sintetske kanabinoide, droge za silovanje i tvari slilčne fentanilu.
Varljen, Sara
core +4 more sources
Novel Drugs of Abuse: What Clinicians Need to Know?
Emerging Trends in Drugs, Addictions, and HealthDrug abuse is a growing concern all over the world, and over the past decade, novel drugs have emerged and have become increasingly popular. Designer drugs—otherwise known as synthetic drugs—are manufactured to chemically resemble illicit drugs but may ...
A. El Mougy
doaj +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, with an overall survival now surpassing 90% in developed countries. However, treatments are not without adverse effects. In this study, we apply the severe toxicity‐free survival (STFS) framework to determine the prevalence of 21 physician‐defined severe ...
Lane Collier +10 more
wiley +1 more source
Rise in ‘designer drugs’ poses serious health risk: UN report. [PDF]
, 2013 Designer drugs are multiplying at a worrying rate and increasingly sending users to hospital, a UN-affiliated report has said, calling for international efforts to stem the spread of these substances.
core
Detection of Drugs of Abuse by Raman Spectroscopy [PDF]
, 2010 Raman spectroscopy can provide rapid, sensitive, non-destructive analysis of a variety of drug types (e.g. amphetamines, alkaloids, designer drugs and date rape drugs). This review concentrates on developments in the past 15 years.
West, M.J. +3 more
core +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Type 1 plasminogen deficiency (PLGD‐1) is an ultra‐rare autosomal recessive disorder caused by variants in the PLG gene and affects approximately 1.6 individuals per million. The condition is characterized by decreased plasminogen levels and impaired function, resulting in fibrin‐rich lesions on mucous membranes throughout the body.
Charles Nakar +7 more
wiley +1 more source
The challenge of synthetic drugs in East and South-East Asia and Oceania [PDF]
, 2015 The demand for synthetic drugs in East and Southeast Asia and Oceania continues to rise, while rapid economic integration is creating new opportunities for transnational criminal groups to expand the illicit drug trade, warns the United Nations Office on
Justice Tettey
core